Last reviewed · How we verify
Ademetionine 2
Ademetionine 2 is a Hepatoprotective agent / Methyl donor Small molecule drug developed by Zhejiang Hisun Pharmaceutical Co. Ltd.. It is currently FDA-approved for Cholestasis and cholestatic liver disease, Hepatic dysfunction and liver support, Drug-induced liver injury.
Ademetionine is a methyl donor that replenishes cellular S-adenosylmethionine (SAM) levels to support methylation reactions and hepatic function.
Ademetionine is a methyl donor that replenishes cellular S-adenosylmethionine (SAM) levels to support methylation reactions and hepatic function. Used for Cholestasis and cholestatic liver disease, Hepatic dysfunction and liver support, Drug-induced liver injury.
At a glance
| Generic name | Ademetionine 2 |
|---|---|
| Sponsor | Zhejiang Hisun Pharmaceutical Co. Ltd. |
| Drug class | Hepatoprotective agent / Methyl donor |
| Target | S-adenosylmethionine (SAM) / cellular methylation pathways |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Ademetionine (also known as S-adenosyl methionine or SAM) is an endogenous compound that serves as the primary methyl donor in cells. It participates in critical methylation reactions involving proteins, lipids, and nucleic acids, and is particularly important for hepatocyte membrane integrity and liver regeneration. By restoring depleted SAM levels, ademetionine supports liver function and may reduce cholestasis and hepatocellular damage.
Approved indications
- Cholestasis and cholestatic liver disease
- Hepatic dysfunction and liver support
- Drug-induced liver injury
Common side effects
- Gastrointestinal disturbances (nausea, diarrhea)
- Headache
- Dizziness
Key clinical trials
- Single-Center Phase II Double-Blind Trial of SAMe to Prevent Liver Cancer in MASLD-Related Cirrhosis (PHASE2)
- Ademetionine in Obstructive Hypertrophic Cardiomyopathy (PHASE2)
- SAMe in Prevention of Oxaliplatin-associated Liver Injury (PHASE2)
- Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia (NA)
- Development of a Diagnostic Prediction Score for Tuberculosis in Hospitalized Children With Severe Acute Malnutrition (TB-Speed SAM) (NA)
- SAMe Trial for Patients With Alcoholic Cirrhosis (PHASE2)
- From Yearly Checks to Daily Progress: Evaluating Goal Attainment Scaling (GAS) in Systematic Work Environment Management (SAM) Within the Municipal Sector (NA)
- Trial of Rice-Based F-75 in Severe Malnutrition & Persistent Diarrhea in Children (SAM-RICE Study) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ademetionine 2 CI brief — competitive landscape report
- Ademetionine 2 updates RSS · CI watch RSS
- Zhejiang Hisun Pharmaceutical Co. Ltd. portfolio CI
Frequently asked questions about Ademetionine 2
What is Ademetionine 2?
How does Ademetionine 2 work?
What is Ademetionine 2 used for?
Who makes Ademetionine 2?
What drug class is Ademetionine 2 in?
What development phase is Ademetionine 2 in?
What are the side effects of Ademetionine 2?
What does Ademetionine 2 target?
Related
- Drug class: All Hepatoprotective agent / Methyl donor drugs
- Target: All drugs targeting S-adenosylmethionine (SAM) / cellular methylation pathways
- Manufacturer: Zhejiang Hisun Pharmaceutical Co. Ltd. — full pipeline
- Therapeutic area: All drugs in Hepatology / Gastroenterology
- Indication: Drugs for Cholestasis and cholestatic liver disease
- Indication: Drugs for Hepatic dysfunction and liver support
- Indication: Drugs for Drug-induced liver injury
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing